JP Morgan Chase’s Adverum Biotechnologies ADVM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-182
| Closed | -$824 | – | 7391 |
|
|
2025
Q3 | $824 | Buy |
+182
| New | +$537 | ﹤0.01% | 6999 |
|
|
2025
Q2 | – | Sell |
-10,198
| Closed | -$44.6K | – | 7031 |
|
|
2025
Q1 | $44.6K | Sell |
10,198
-20,466
| -67% | -$92.2K | ﹤0.01% | 5919 |
|
|
2024
Q4 | $143K | Buy |
30,664
+21,274
| +227% | +$143K | ﹤0.01% | 5612 |
|
|
2024
Q3 | $65.9K | Buy |
9,390
+486
| +5% | +$3.53K | ﹤0.01% | 5885 |
|
|
2024
Q2 | $61.1K | Buy |
8,904
+8,866
| +23,332% | +$82.4K | ﹤0.01% | 5769 |
|
|
2024
Q1 | $537 | Sell |
38
-3
| -7% | -$46 | ﹤0.01% | 6706 |
|
|
2023
Q4 | $305 | Hold |
41
| – | – | ﹤0.01% | 7007 |
|
|
2023
Q3 | $608 | Sell |
41
-142
| -78% | -$2.55K | ﹤0.01% | 6698 |
|
|
2023
Q2 | $2.9K | Sell |
183
-120,838
| -100% | -$1.27M | ﹤0.01% | 6283 |
|
|
2023
Q1 | $868K | Hold |
121,021
| – | – | ﹤0.01% | 4148 |
|
|
2022
Q4 | $701K | Sell |
121,021
-403
| -0.3% | -$3.06K | ﹤0.01% | 4291 |
|
|
2022
Q3 | $1.15M | Sell |
121,424
-41,709
| -26% | -$548K | ﹤0.01% | 3893 |
|
|
2022
Q2 | $1.96M | Sell |
163,133
-5,594
| -3% | -$58.6K | ﹤0.01% | 3563 |
|
|
2022
Q1 | $2.21M | Sell |
168,727
-37,369
| -18% | -$547K | ﹤0.01% | 3665 |
|
|
2021
Q4 | $3.63M | Sell |
206,096
-20,561
| -9% | -$412K | ﹤0.01% | 3330 |
|
|
2021
Q3 | $4.92M | Sell |
226,657
-7,377
| -3% | -$188K | ﹤0.01% | 3037 |
|
|
2021
Q2 | $8.19M | Buy |
234,034
+36,488
| +18% | +$1.97M | ﹤0.01% | 2603 |
|
|
2021
Q1 | $19.5M | Buy |
197,546
+140,745
| +248% | +$16.9M | ﹤0.01% | 1784 |
|
|
2020
Q4 | $6.16M | Buy |
56,801
+18,941
| +50% | +$2.34M | ﹤0.01% | 2625 |
|
|
2020
Q3 | $3.96M | Buy |
37,860
+8,477
| +29% | +$1.27M | ﹤0.01% | 2753 |
|
|
2020
Q2 | $6.14M | Buy |
29,383
+8,027
| +38% | +$1.42M | ﹤0.01% | 2305 |
|
|
2020
Q1 | $2.09M | Sell |
21,356
-51,958
| -71% | -$6.06M | ﹤0.01% | 2937 |
|
|
2019
Q4 | $8.45M | Sell |
73,314
-26,205
| -26% | -$2.31M | ﹤0.01% | 2259 |
|
|
2019
Q3 | $5.42M | Sell |
99,519
-164,735
| -62% | -$18.6M | ﹤0.01% | 2642 |
|
|
2019
Q2 | $29.1M | Sell |
264,254
-65,525
| -20% | -$5.42M | 0.01% | 1289 |
|
|
2019
Q1 | $17.3M | Buy |
329,779
+37,146
| +13% | +$1.5M | ﹤0.01% | 1639 |
|
|
2018
Q4 | $9.22M | Buy |
292,633
+15,924
| +6% | +$648K | ﹤0.01% | 2084 |
|
|
2018
Q3 | $16.7M | Buy |
276,709
+21,477
| +8% | +$1.21M | ﹤0.01% | 1804 |
|
|
2018
Q2 | $13.5M | Buy |
255,232
+55,491
| +28% | +$3.34M | ﹤0.01% | 1901 |
|
|
2018
Q1 | $11.6M | Buy |
199,741
+186,480
| +1,406% | +$11.6M | ﹤0.01% | 1916 |
|
|
2017
Q4 | $464K | Buy |
13,261
+2,960
| +29% | +$97.4K | ﹤0.01% | 4098 |
|
|
2017
Q3 | $355K | Buy |
10,301
+3,025
| +42% | +$84K | ﹤0.01% | 3935 |
|
|
2017
Q2 | $182K | Sell |
7,276
-2,256
| -24% | -$61.7K | ﹤0.01% | 4010 |
|
|
2017
Q1 | $258K | Sell |
9,532
-1,424
| -13% | -$40.5K | ﹤0.01% | 3979 |
|
|
2016
Q4 | $317K | Buy |
10,956
+6,185
| +130% | +$202K | ﹤0.01% | 3968 |
|
|
2016
Q3 | $196K | Buy |
4,771
+1,546
| +48% | +$58.6K | ﹤0.01% | 3694 |
|
|
2016
Q2 | $102K | Sell |
3,225
-4,922
| -60% | -$222K | ﹤0.01% | 3876 |
|
|
2016
Q1 | $421K | Sell |
8,147
-425
| -5% | -$23.7K | ﹤0.01% | 3400 |
|
|
2015
Q4 | $816K | Sell |
8,572
-52
| -0.6% | -$4.57K | ﹤0.01% | 3202 |
|
|
2015
Q3 | $711K | Sell |
8,624
-55,708
| -87% | -$7.12M | ﹤0.01% | 3280 |
|
|
2015
Q2 | $10.4M | Sell |
64,332
-2,014
| -3% | -$680K | ﹤0.01% | 1898 |
|
|
2015
Q1 | $26.9M | Sell |
66,346
-6,166
| -9% | -$2.61M | 0.01% | 1242 |
|
|
2014
Q4 | $39.2M | Buy |
72,512
+27,737
| +62% | +$10.7M | 0.01% | 1061 |
|
|
2014
Q3 | $15.3M | Buy |
+44,775
| New | +$13.3M | ﹤0.01% | 1617 |
|
JP Morgan Chase's ADVM Position: Q4 2025 in Review
JP Morgan Chase sold out of Adverum Biotechnologies (ADVM) in Q4 2025, closing a stake of 182 shares — an estimated $824 sold.
JP Morgan Chase first reported a position in ADVM in Q3 2014 and held it in 44 quarters. The position peaked at $39.2M in Q4 2014. 0 funds tracked by Wall St. Rank hold ADVM as of Q4 2025.
- JP Morgan Chase reported no remaining Adverum Biotechnologies position as of Q4 2025 after selling out during the quarter.
- JP Morgan Chase sold 182 Adverum Biotechnologies shares in Q4 2025, an estimated $824.
- JP Morgan Chase first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 44 quarters.
- JP Morgan Chase's Adverum Biotechnologies position peaked at $39.2M in Q4 2014.
- 0 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2025.
Based on JP Morgan Chase's 13F filing for Q4 2025, filed 11 Feb 2026.